نتایج جستجو برای: factor viii and factor ix inhibitor

تعداد نتایج: 16983528  

2017
Tarek Owaidah Abdulkareem Al Momen Hazzaa Alzahrani Abdulrahman Almusa Fawaz Alkasim Ahmed Tarawah Randa Al Nouno Fatima Al Batniji Fahad Alothman Ali Alomari Saud Abu-Herbish Mahmoud Abu-Riash Khawar Siddiqui Mansor Ahmed SY Mohamed Mahasen Saleh

Hemophilia A and B are X-linked diseases that predominantly affect male patients. Patients can develop coagulation factor inhibitors, which exponentially increases the treatment cost. However, the prevalence of factor VIII and IX inhibitors in Saudi Arabia is unclear.This study aimed to determine the Saudi prevalence of factor VIII and IX inhibitors.This 4-year, 7-center, cross-sectional study ...

Journal: :Blood 2000
A van Hylckama Vlieg I K van der Linden R M Bertina F R Rosendaal

Elevated plasma levels of factor VIII (> 150 IU/dL) are an important risk factor for deep vein thrombosis (DVT). Factor VIII is the cofactor of factor IXa in the activation of factor X. The risk of thrombosis in individuals with an elevated factor IX level is unknown. This study investigated the role of elevated factor IX levels in the development of DVT. We compared 426 patients with a first o...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1984
D M Stern M Drillings W Kisiel P Nawroth H L Nossel K S LaGamma

Previous studies have shown that factor IX and its activated form, factor IXa, bind to cultured vascular endothelial cells and that cell-bound factor IXa retains its procoagulant activity. The present studies provide evidence that factor IX bound to cultured bovine aortic endothelial cells can be activated. Factor IX activation was assessed by finding cleavage of the factor IX molecule on NaDod...

Journal: :American Society for Clinical Laboratory Science 2019

Journal: :Blood 1997
C van 't Veer N J Golden M Kalafatis P Simioni R M Bertina K G Mann

The classification of factor VIII deficiency, generally used based on plasma levels of factor VIII, consists of severe (<1% normal factor VIII activity), moderate (1% to 4% factor VIII activity), or mild (5% to 25% factor VIII activity). A recent communication described four individuals bearing identical factor VIII mutations. This resulted in a severe bleeding disorder in two patients who carr...

2009
Yang Buyue John P. Sheehan

Depolymerized holothurian glycosaminoglycan (DHG) is a fucosylated chondroitin sulfate with antithrombin-independent antithrombotic properties. Heparin cofactor II (HCII)-dependent and -independent mechanisms for DHG inhibition of plasma thrombin generation were evaluated. When thrombin generation was initiated with 0.2 pM tissue factor (TF), the half maximal effective concentration (EC50) for ...

2005
Catherine Driscoll Eric Bouhassira Louis M. Aledort

Hemophilia B is an X-Iinked recessive bleeding disorder resulting from a deficiency of the coagulation factor IX (FIX) protein activity. a vitamin K-dependent serine protease active in both the intrinsic and extrinsic coagulation systems. DNA analyses of the factor IX gene in two unrelated patients with severe hemophilia B. with a IX coagulant activity <1 % and undetectable FIX antigen. detecte...

Journal: :Blood 2009
Yang Buyue John P Sheehan

Depolymerized holothurian glycosaminoglycan (DHG) is a fucosylated chondroitin sulfate with antithrombin-independent antithrombotic properties. Heparin cofactor II (HCII)-dependent and -independent mechanisms for DHG inhibition of plasma thrombin generation were evaluated. When thrombin generation was initiated with 0.2 pM tissue factor (TF), the half maximal effective concentration (EC(50)) fo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید